FDA Rejects Capricor's Duchenne Cell Therapy, Deramiocel
CAPR is trading near its 52-week low of $2.96 (28% below the low) on elevated volume (2.9× avg).
Summary
The FDA declined to approve deramiocel, Capricor's cell therapy for Duchenne muscular dystrophy, on Friday — a complete rejection of the company's lead asset rather than the approval the November 22 PDUFA date had set up. The complete response letter said available data did not provide substantial evidence of efficacy and cited serious deficiencies in the deramiocel study; Capricor is reviewing the letter and will announce next steps. This is the binary event the stock has been trading on: shares sit at $2.12, near a 52-week low of $2.96 and far below the $40.37 high, so the market had already priced heavy skepticism. The setup had been deteriorating — the August 24 PDUFA extension to November 22, a HOPE-3 secondary endpoint on LVEF that missed statistical significance at p=0.09 on November 9, and a Q3 loss of $42.7 million that cut cash and securities to $198.5 million from $318.1 million at year-end. With no approval, Capricor has no near-term revenue path for deramiocel and must decide whether to run another trial or seek a partner on a program the FDA has now turned down.
Updated with a Binance News report · What changed
Updates
· Binance News — The complete response letter said available data did not provide substantial evidence of efficacy and cited serious deficiencies in the deramiocel study; Capricor is reviewing the letter and will announce next steps.
At the time of this announcement, CAPR was trading at $2.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $441.3M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with negative market sentiment and an importance score of 10 out of 10. Source: Reuters.